Linked Life Data

12240712

Source:http://linkedlifedata.com/resource/pubmed/id/12240712

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-9-20
pubmed:abstractText
The science of medicine has evolved dramatically over recent years, with better understanding of the mechanisms of disease leading to innovative new treatments. However, the critical care patient still suffers from a high mortality rate with few advances from the traditional modalities of therapy. Arginine vasopressin has been explored as a vasoconstrictor in the treatment of the hypotension associated with septic shock. This drug has also recently been added to the advanced cardiac life support protocol for the resuscitation of pulseless ventricular tachycardia and ventricular fibrillation. Studies of arginine vasopressin in these situations have been promising but still have yet to prove a survival benefit over traditional therapies. Newer and larger trials are necessary to determine whether any mortality benefit can be sustained from the use of arginine vasopressin in critical care patients with septic shock and cardiac arrest secondary to pulseless ventricular tachycardia and ventricular fibrillation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0002-9629
pubmed:author
pubmed:issnType
Print
pubmed:volume
324
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
146-54
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Vasopressin: new uses in critical care.
pubmed:affiliation
University of Texas Southwestern Medical Center, Department of Internal Medicine, Dallas 75235, USA. peterchen@softhome.net
pubmed:publicationType
Journal Article, Review